Monday, November 11, 2019
- 9:00AM-11:00AM
-
Abstract Number: 1577
The Impact of the New American College of Cardiology/American Heart Association Definition of Hypertension on Cardiovascular Events in Systemic Lupus Erythematosus
SLE – Clinical Poster II: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1484
The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1456
The Increased Ratio of Blood CD56bright to CD56dim NK Cells Is a Distinguishing Feature of Primary Sjögren’s Syndrome
Sjögrenʼs Syndrome – Basic & Clinical Science Poster II- 9:00AM-11:00AM
-
Abstract Number: 1017
The Integration of Genetic Data, Molecular Pathway Analysis and Differential Expression to Delineate the Impact of Ancestral Differences on Lupus
SLE – Etiology & Pathogenesis Poster I- 9:00AM-11:00AM
-
Abstract Number: 1690
The Long-term Outcome of Patients with Arthritis of Behçet’s Disease
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides- 9:00AM-11:00AM
-
Abstract Number: 1043
The Metabolic Intermediate Alpha-Ketoglutarate Suppresses the TGFβ-driven Profibrotic Responses of Dermal Fibroblasts
Systemic Sclerosis & Related Disorders – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 1327
The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial
Osteoarthritis – Clinical Poster I- 9:00AM-11:00AM
-
Abstract Number: 1464
The Oral Microbiome as a Risk Factor for Benign or Pathologic Autoimmunity Associated with Anti-SSA/Ro Positivity and Mimicry for Von Willebrand Factor Type a Domain Protein (vWFA) of L. Mirabilis
Sjögrenʼs Syndrome – Basic & Clinical Science Poster II- 9:00AM-11:00AM
-
Abstract Number: 1328
The Patient’s Perspective on a Disease Flare During Tapering of DMARDs in Rheumatoid Arthritis
RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures- 9:00AM-11:00AM
-
Abstract Number: 1533
The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1052
The PPAR Agonist Lanifibranor Protects Against Right Ventricular Hypertrophy in a Mouse Model of Systemic Sclerosis Associated Pulmonary Hypertension
Systemic Sclerosis & Related Disorders – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 962
The Presence of Circulating CD19+CD21lo cells Predicts the Presence of Interstitial Lung Disease in Patients with Systemic Sclerosis
B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 1263
The Prevalence and Patterns of Celiac Disease Associated Arthropathy and Coexistence of Celiac Disease with Rheumatic Disorders in a Single Tertiary Medical Center
Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies